Veradermics, Incorporated Statistics
Want to see MANE full AI Analyst Report?
Veradermics, Incorporated (MANE) Stock Statistics & Valuation Metrics
Total Valuation
Veradermics, Incorporated has a market cap or net worth of $5.47B. The enterprise value is $4.32B.
- Market Cap
- $5.47B
- Enterprise Value
- $4.32B
Share Statistics
Veradermics, Incorporated has 42,195,473 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 42,195,473
- Owned by Insiders
- 16.66%
- Owned by Institutions
- 29.71%
Financial Efficiency
Veradermics, Incorporated’s return on equity (ROE) is 0.58 and return on invested capital (ROIC) is -50.43%.
- Return on Equity (ROE)
- 0.58
- Return on Assets (ROA)
- -0.46
- Return on Invested Capital (ROIC)
- -50.43%
- Return on Capital Employed (ROCE)
- -0.50
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.37M
- Employee Count
- 51
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Veradermics, Incorporated is -49.11. Veradermics, Incorporated’s PEG ratio is 1.28.
- PE Ratio
- -49.11
- PS Ratio
- 0.00
- PB Ratio
- 6.86
- Price to FCF
- -66.23
- Price to Operating Cash Flow
- -66.41
- PEG Ratio
- 1.28
Income Statement
In the last 12 months, Veradermics, Incorporated had revenue of 0 and earned -70.00M in profits. Earnings per share was -111.91.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -72.35M
- Pretax Income
- -70.00M
- Net Income
- -70.00M
- EBITDA
- -70.00M
- Earnings Per Share (EPS)
- -111.91
Cash Flow
In the last 12 months, operating cash flow was -82.23M and capital expenditures -372,000, giving a free cash flow of -82.60M billion.
- Operating Cash Flow
- -82.23M
- Free Cash Flow
- -82.60M
- Free Cash Flow per Share
- -1.96
Dividends & Yields
Veradermics, Incorporated pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.51%
- Earnings Yield
- -1.71%
Stock Price Statistics
- Beta
- 0.19
- 52-Week Price Change
- 243.47%
- 50-Day Moving Average
- 122.23
- 200-Day Moving Average
- 96.14
- Relative Strength Index (RSI)
- 48.04
- Average Volume (3m)
- 755.78K
Important Dates
Veradermics, Incorporated upcoming earnings date is Apr 05, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 10, 2026
- Next Earnings Date
- Apr 05, 2027
- Ex-Dividend Date
- ―
Financial Position
Veradermics, Incorporated as a current ratio of 16.66, with Debt / Equity ratio of -0.00%
- Current Ratio
- 16.66
- Quick Ratio
- 16.66
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.31
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Veradermics, Incorporated has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Veradermics, Incorporated EV to EBITDA ratio is -53.88, with an EV/FCF ratio of -64.64.
- EV to Sales
- 0.00
- EV to EBITDA
- -53.88
- EV to Free Cash Flow
- -64.64
- EV to Operating Cash Flow
- -64.93
Balance Sheet
Veradermics, Incorporated has $798.35M in cash and marketable securities with $668.00K in debt, giving a net cash position of $797.68M billion.
- Cash & Marketable Securities
- $798.35M
- Total Debt
- $668.00K
- Net Cash
- $797.68M
- Net Cash Per Share
- $18.90
- Tangible Book Value Per Share
- $18.91
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Veradermics, Incorporated is $180.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $180.67
- Price Target Upside
- 39.34% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -57.61%
Scores
- Smart Score
- 8
- AI Score
- 54

